Congenital Hyperinsulinism clinical trials at UCLA
1 research study open to eligible people
open to eligible people ages 2 years and up
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC). HM15136 will be administered once weekly in multiple doses to subjects in multiple age including pediatric to find appropriate exposure-response data.
Los Angeles, California and other locations
Our lead scientists for Congenital Hyperinsulinism research studies include Erin Okawa.